Seeking Alpha

Clovis rallies on new CO-1686 data

  • Clovis Oncology (CLVS +0.5%) rises after updating investors on its EGFR inhibitor CO-1686.
  • CLVS says partial responses (RECIST) were observed in nine T790M positive patients (67% objective response rate). At ASCO, only four T790M positive patients were evaluable.
  • Eight of those patients (89%) "experienced tumor shrinkage greater than 10%." (PR)
Comments (1)
  • Crash survivor87
    , contributor
    Comments (61) | Send Message
    A partial response is defined as a shrinkage of LD. The shrinkage
    has to be greater than 30%!!
    10% is just a stable disease.
    29 Oct 2013, 12:08 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: